Sublingual vs Capsule NAD+ Supplements: Delivery Claims and Evidence

“Sublingual” and “capsule” do not identify the molecule, amount, formulation, or clinical outcome. A sublingual product might contain NAD+, NMN, NR, NMNH, or another ingredient. A capsule might contain one precursor or a proprietary blend. Route claims must match the exact material and a direct human comparison.

In 2026, a small randomized crossover study directly compared sublingual and oral NMN in 14 healthy adult men. It found higher early exposure to terminal metabolites 2PY and 4PY after sublingual administration, but no significant route difference in blood NMN, nicotinamide, or NAD+ during the 60-minute sampling period. Read the study.

That result is more precise than “sublingual absorbs better.” It concerns one NMN material, two administration protocols, specific metabolites, 14 men, and one hour.

Compare all route fields

The label must be read before the route is compared.

What the 2026 NMN study does not show

The study's authors were employees of the company that conducted the research, a relevant conflict to record. No adverse events were reported in the acute protocol. The metabolic origin of the higher terminal catabolites could not be distinguished.

Higher 2PY and 4PY over 60 minutes does not demonstrate greater delivery of NMN to a target tissue, a larger sustained NAD+ increase, improved energy, slower aging, or superior long-term safety. The absence of a significant difference in blood NMN or NAD+ also does not prove the routes are identical under every dose and duration.

Most critically, the result cannot be transferred to sublingual NAD+, NR, or NMNH products. It tested NMN. A mouth-dissolving dosage form can also be swallowed partly or completely, making “bypasses digestion” an assumption unless the study verifies route and absorption.

Capsule evidence belongs to its molecule

A placebo-controlled trial gave 250 mg per day of oral NMN to 30 healthy adults for 12 weeks and reported increased whole-blood NAD+ under its protocol. Read the oral NMN trial. That study provides longer-duration capsule evidence for its NMN material, not a direct comparison with sublingual use and not evidence for NMNH.

An open-label study in eight healthy volunteers evaluated oral nicotinamide riboside and whole-blood NAD+ pharmacokinetics. Read the NR study. The small, uncontrolled design and different molecule prevent a route ranking.

The evidence base should therefore be arranged by molecule first and route second. Combining an NR capsule trial with an NMN sublingual trial would confound both fields.

The NAD+ supplement buyer's guide provides a broader label checklist. The NMNH versus NMN guide explains the chemical distinction that route marketing often hides.

Do not open or dissolve ordinary capsules

A capsule's shell and contents are designed for the labeled use. Opening it can change taste, exposure to moisture and oxygen, dosing accuracy, and where the ingredients release. Some contents can irritate the mouth or have excipients not evaluated for sublingual contact.

Do not hold capsule powder under the tongue, dissolve it, chew it, or divide it unless the finished-product directions explicitly permit that use. A general theory about first-pass metabolism is not authorization to change the route.

The FDA's Supplement Facts labeling guide explains serving information, while the NIH dietary-supplement overview emphasizes reading labels and discussing supplement use with health professionals.

Absorption is not a clinical outcome

Pharmacokinetics can measure peak concentration, time to peak, area under the curve, or metabolite exposure. A route can change one measure without changing another. A higher peak can be shorter-lived, and a metabolite increase may not identify the route to a target tissue.

Clinical value requires an outcome relevant to the user, adequate duration, appropriate comparator, and safety monitoring. “Bypasses the digestive system” and “100% bioavailable” require direct evidence and a defined denominator. A dissolving tablet's disappearance in the mouth does not prove complete systemic absorption.

Granver's claims-review framework explains why PK, biomarker, symptom, and clinical outcomes must remain separate.

What NAD+ Supreme uses

NAD+ Supreme is a capsule product with a two-capsule serving. Its 220 mg Proprietary Rejuvenation Complex lists proprietary NMNH, L-ergothioneine, Goldgin ginseng, and PowerGrape. The individual NMNH amount is not disclosed, and the product is not labeled for sublingual use.

Do not open the capsules to imitate an NMN sublingual study. The product contains a different precursor in a multi-ingredient blend, and the cited 2026 study did not test the formula.

Review the current NAD+ Supreme product page and follow its directions. The NAD+ cellular-energy guide places delivery claims within the broader outcome evidence.

A route-claim checklist

1. Name the exact molecule and salt or chemical form.
2. Record the individual amount and formulation.
3. Confirm the labeled administration route.
4. Find a direct human route comparison using the same material.
5. Record sampling duration and every measured analyte.
6. Separate significant from nonsignificant results.
7. Record clinical outcomes, adverse events, funding, and conflicts.
8. Do not transfer percentages to another molecule or finished product.

This checklist can produce “unknown” as the answer. That is more accurate than ranking formats from marketing language.

Timing language can hide the comparison

A sublingual study may sample the first hour densely, while a capsule trial may measure a morning trough after weeks of use. The first design describes acute kinetics; the second describes a steady-state or longer-term response. Neither is automatically more meaningful, and their graphs cannot be overlaid as a route contest.

Record whether participants were fasting, whether they swallowed saliva, how long the material remained under the tongue, and whether food or drink was restricted. For capsules, record fed or fasted conditions, shell type, release design, and adherence. Missing administration details limit reproducibility.

A product format is more than its route

Sublingual tablets need acceptable taste, dissolution, dose uniformity, and stability in the package. Capsules need content uniformity, disintegration, and protection from moisture or light when relevant. Excipients can change dissolution and tolerability in both formats.

A supplier's raw-powder absorption claim cannot establish the finished tablet or capsule's performance. Look for a study or validated test tied to the actual formulation. If a seller provides only a diagram showing veins under the tongue, the evidence remains unknown.

Injection evidence is a third category

Intravenous or intramuscular NAD-related treatments use a medical administration route with different exposure, risks, monitoring, and regulatory context. An infusion bypasses the gastrointestinal tract, but that fact does not validate a sublingual supplement or tell consumers to imitate clinical dosing.

Do not use injection case reports or clinic protocols to rank retail tablets and capsules. The exact molecule, sterility, administered amount, infusion rate, patient population, and adverse-event monitoring differ fundamentally.

Clinical outcomes still decide usefulness

Even if future research establishes a route difference for one precursor, the next question is whether it changes a meaningful outcome at acceptable risk. Studies should report symptoms, function, validated health endpoints, adherence, adverse events, and not only a brief metabolite curve.

Until such evidence exists for a finished product, describe delivery accurately and avoid “fastest,” “most bioavailable,” or “best” language. The 2026 NMN study is useful because it narrows the claim rather than proving a winner.

FAQs

Your next step

Use the route-claim checklist and follow the current NAD+ Supreme directions without opening or repurposing its capsules.

Educational information only. Granver products are dietary supplements and are not intended to diagnose, treat, cure, or prevent disease. This article does not replace individualized medical care.